Skip to main content
NCBI home page
Frontiers in Genetics logoLink to Frontiers in Genetics
. 2013 Jun 24;4:120. doi: 10.3389/fgene.2013.00120

Extracellular circulating viral microRNAs: current knowledge and perspectives

Alessandro Laganà 1,*,†, Francesco Russo 2,3,†, Dario Veneziano 1,2, Sebastiano Di Bella 2, Rosalba Giugno 2,‡, Alfredo Pulvirenti 2,‡, Carlo M Croce 1, Alfredo Ferro 2,*
PMCID: PMC3690336  PMID: 23805153

Abstract

MicroRNAs (miRNAs) are small non-coding RNAs responsible of post-transcriptional regulation of gene expression through interaction with messenger RNAs (mRNAs). They are involved in important biological processes and are often dysregulated in a variety of diseases, including cancer and infections. Viruses also encode their own sets of miRNAs, which they use to control the expression of either the host’s genes and/or their own. In the past few years evidence of the presence of cellular miRNAs in extracellular human body fluids such as serum, plasma, saliva, and urine has accumulated. They have been found either cofractionate with the Argonaute2 protein or in membrane-bound vesicles such as exosomes. Although little is known about the role of circulating miRNAs, it has been demonstrated that miRNAs secreted by virus-infected cells are transferred to and act in uninfected recipient cells. In this work we summarize the current knowledge on viral circulating miRNAs and provide a few examples of computational prediction of their function.

Keywords: microRNA, viruses, exosomes, circulating microRNA, vesicules, body fluids

INTRODUCTION

MicroRNAs (miRNAs) are the most studied and best characterized molecules in the class of small regulatory non-coding RNAs (Bartel, 2009). They are involved in several important biological processes and functions through post-transcriptional regulation of the expression of messenger RNAs (mRNAs), and their dysregulation is often cause or consequence of a variety of diseases, such as cancer and neurodegenerative disorders (Croce, 2009; Eacker et al., 2009). Cellular miRNAs can be packaged into different carriers and exported to recipient cells or released in small vesicles during apoptosis (Boon and Vickers, 2013; Hilton and Karpe, 2013). The discovery of extracellular miRNAs in biological fluids has started a new exciting field of research. Circulating miRNAs are now considered useful markers of disease conditions and functional mediators of several biological processes in a novel form of cell-to-cell communication. A novel useful resource is the database miRandola, which provides users with a comprehensive manually curated classification of extracellular circulating miRNAs (Russo et al., 2012).

Viruses encode their own sets of miRNAs. Evidence shows that these miRNAs can act as self-regulators of viral gene expression and/or control host cell pathways through silencing of their nodes (Kincaid and Sullivan, 2012). Some viruses can exploit extracellular particles for the initiation and progression of the infection and recent evidence indicates that viruses can export and deliver functional miRNAs through vesicles (Pegtel et al., 2010). This discovery reveals a new layer in the infectious mechanism used by viruses to maintain their latency and control crucial host pathways whose targeting is likely beneficial to the virus.

In this mini review we summarize the current knowledge about circulating miRNAs and their potential regulatory functions, with particular emphasis on extracellular viral miRNAs. We report the promising results of the most recent studies and provide a few examples of computational prediction of viral miRNA function.

CURRENT KNOWLEDGE

CIRCULATING miRNAs ARE FUNCTIONAL IN RECIPIENT CELLS AND CONSTITUTE USEFUL BIOMARKERS FOR VARIOUS CONDITIONS

Extracellular miRNAs have been recently identified stable in most biological fluids, including blood, urine, saliva, semen, cerebrospinal fluid, and breast milk (Mitchell et al., 2008; Hanke et al., 2010; Wang et al., 2011; Alexandrov et al., 2012; Gallo et al., 2012; Zhou et al., 2012). Evidence shows that they may be selectively packaged into different kinds of carriers, such as membrane-derived vesicles, lipoproteins, and ribonucleoprotein complexes, which protect them from degradation and export them to recipient cells where they exert their regulatory functions. Particularly, exosomes and microparticles (MPs) are two distinct classes of small membrane-enclosed vesicles released from cells, differing in size, biogenesis, and secretory mechanisms (Boon and Vickers, 2013). Exosomes are produced by the inward budding of the limiting membrane of multivesicular bodies (MVBs). They are smaller than MPs, which are instead formed by the outward budding and blebbing of the plasma membrane. Small sealed membrane vesicles that are produced from cells during apoptosis, called apoptotic bodies, can also transport specific sets of miRNAs. Extracellular miRNAs have also been found in high-density lipoproteins (HDL) and low-density lipoproteins (LDL), and bound to Argonaute 2 (AGO2) and other ribonucleoproteins, both in and out of membrane-derived vesicles (Arroyo et al., 2011; Turchinovich et al., 2011; Vickers and Remaley, 2012; Rayner and Hennessy, 2013). Viral surface antigen particles may also carry specific miRNAs, as in the case of hepatitis B surface antigen particles which contain hepatocellular miRNAs bound to AGO2 (Novellino et al., 2012).

MicroRNA profiles of extracellular carriers show distinct sets of miRNAs than their parent cell-type, thus suggesting that some miRNAs might be transcribed only to be exported and not retained in the parent cell (Ohshima et al., 2010; Pigati et al., 2010). Selective packaging of miRNAs into vesicles is probably related to the specific biological functions of the secreted miRNAs.

Circulating miRNAs are highly stable and consistent among individuals of the same species. Specific miRNA expression signatures in extracellular environment have been identified in a variety of human diseases, including cancer and neurological diseases, revealing the diagnostic potential of circulating miRNAs as useful non-invasive biomarkers (Alexandrov et al., 2012; Fayyad-Kazan et al., 2013; Zeng et al., 2013).

Several in vitro studies have shown that miRNAs transferred by the different types of carriers are functional and can regulate gene expression in recipient cells.

Apoptotic bodies generated from endothelial cells during atherosclerosis were shown to contain miR-126, which controls endothelial cell signaling in vitro and provides atheroprotective effects in vivo (Zernecke et al., 2009).

Another study showed that endothelial cells can transfer functional miR-143 and miR-145 to smooth muscle cells where they mediate the reduction of atherosclerotic lesion formation in vivo (Hergenreider et al., 2012).

Similarly, circulating miR-150 is released by monocytes and taken up by endothelial cells where it regulates endothelial cell migration (Zhang et al., 2010).

Although the complete mechanism of gene regulation mediated by specifically selected extracellular circulating miRNAs has yet to be clearly demonstrated in vivo, these studies suggest a plausible form of cell-to-cell communication in which donor cells send their miRNAs to distant recipient cells where they exert their regulatory functions.

VIRUSES EXPLOIT EXTRACELLULAR PARTICLES TO ESTABLISH AND MAINTAIN THE INFECTION

It has been shown that some viruses exploit extracellular particles, such as microvesicles, for the initiation and progression of the infection (Meckes and Raab-Traub, 2011). According to the trojan exosome hypothesis proposed by Gould et al. (2003), retroviruses may use the pre-existing non-viral exosome biogenesis and uptake pathways for the formation, release, and delivery of viral particles.

This has been later supported by evidence that some viruses utilize endosomal compartments of the host to generate exosome-like vesicles (Hosseini et al., 2013) which can play different roles in the infection, contributing to its spreading (Mack et al., 2000), favoring exosomal biogenesis (daSilva et al., 2009), and providing immune evasion (Temme et al., 2010).

Viral exosomes, for instance, affect the host immune system in different ways according to the type of virus and the stage of its life cycle in which exosome secretion occurs in the infected host. As proving example, during the non-replicative stage, dendritic cells serve as transit location for HIV-1 (human immunodeficiency virus 1) which exploits their intracellular vesicle trafficking pathways to release antigens and viral particles into the extracellular space and trans-infect CD4+ T cells (Izquierdo-Useros et al., 2010).

Generally, viruses implement different strategies during infection essentially consisting in escaping the host immune system and facilitating the invasion and proliferation within the host. Observations suggest that the release of microvesicles containing specific cellular and viral components by infected cells contributes greatly to the preservation of the virus even in a hostile antiviral immune environment (de Gassart et al., 2003; Izquierdo-Useros et al., 2009; Klibi et al., 2009; György et al., 2011; Meckes and Raab-Traub, 2011).

Epstein–Barr virus (EBV), cytomegalovirus (CMV), and hepatitis C virus (HCV) have found means to evade immune responses and increase virus-fusing ability and infectivity by exploiting microvesicles, giving rise to a systematic distribution of viral agents from infected cells able to induce genetic and epigenetic modifications in recipient cells (Masciopinto et al., 2004; Klibi et al., 2009; Plazolles et al., 2011; Wurdinger et al., 2012).

Tumor-associated viruses, like EBV, may use exosomal transfer to manipulate the growth characteristics of neighboring cells and enhance tumor progression. In particular, exosomes released from nasopharingeal carcinoma (NPC) cells harboring latent EBV were shown to contain the EBV latent membrane protein 1 (LMP1; Meckes et al., 2010), which is frequently expressed in EBV-associated cancers and has potent effects on cell growth by inducing growth-stimulating signaling pathways (Wang et al., 1985; Kaye et al., 1993) and may modulate the selective sorting of proteins into exosomes, favoring important signaling molecules frequently activated in cancers such as phosphatidylinositol 3-kinase (PI3K) and epidermal growth factor receptor (EGFR; Meckes et al., 2010).

VIRUSES ENCODE miRNAs

RNA interference (RNAi) most probably was originally selected as a primary mechanism of defense against harmful genetic elements such as viruses. It is of relevant interest that in the evolutionary selection this mechanism was in turn exploited by viruses to their advantage while, as suggested by tenOever (2013), chordate use of small RNAs might exclusively have shifted to the silencing of genome-encoded transcripts and would at least not pose direct threat to RNA viral genome.

The first report of viral-encoded miRNAs was published by Pfeffer et al. (2004) describing the cloning of viral miRNAs from cells infected with EBV. Among DNA viruses, which account for the majority of known virus-encoded miRNAs, 95% of viral miRNAs known today are of herpesvirus origin.

The majority of natural viruses found to encode miRNAs have thus a DNA component to their replication cycle, can exploit the initiating host miRNA biogenesis machinery in the nucleus where they replicate, and cause long-term persistent infections. DNA viruses such as the ones belonging to the Herpesvirus, Polyomavirus, Ascovirus, Baculovirus, Iridovirus, and Adenovirus families clearly match these characteristics (Sullivan et al., 2005; Gottwein et al., 2007; Choy et al., 2008; Hussain et al., 2008; Seo et al., 2009; Seto et al., 2010; Bauman et al., 2011; Marquitz et al., 2011; Suffert et al., 2011; Zhao et al., 2011; Lee et al., 2012) along with at least one member of the retrovirus family, bovine leukemia virus (BLV), which clearly encodes numerous miRNAs (Kincaid et al., 2012).

Despite the established case of BLV, viruses possessing positive or negative sense RNA or double-stranded RNA (dsRNA) genome are not widely accepted to naturally express miRNAs.

Nevertheless, HIV-1 has been proven to encode two miRNAs and potentially a third. In fact, hiv1-mir-H1 was proven to be responsible for inducing apoptosis and repressing host gene expression (Kaul et al., 2009), while hiv-1-miR-N367 has been suggested as functional ortholog of hsa-miR192 (You et al., 2012). Finally, some evidence is present that the HIV-1 TAR element could be a potential viral miRNA (Houzet and Jeang, 2011), also considering its capability to target pro-apoptotic genes (Klase et al., 2009).

All viral miRNAs can essentially be grouped into two classes: host analogs and virus-specific. Generally, though, their functions include prolonging longevity of infected cells, evading the immune response, and regulating host or viral genes to limit the lytic cycle. Interestingly, all these functions are essential for infections to be persistent.

In fact, miRNAs are likely invisible to the adaptive immune system – a valuable trait for viruses that undergo persistent infection (Cullen, 2006). Thus, in viruses that establish a long-lasting latent infection, such as herpesviruses, one important benefit they could gain from employing miRNAs is the ability to regulate host and/or viral gene expression without having to elicit an antigenic immune reaction or directly suppressing components of the host immune system (Sullivan, 2008).

Preventing cell death seems an obvious advantage to viruses that cause persistent or latent infections. Several different viruses including Kaposi’s sarcoma-associated herpesvirus (KSHV), EBV, and Marek’s Disease Virus type 1 (MDV1) encode miRNAs that can play a subtle role in preventing apoptosis by targeting pro-apoptotic host genes and are also associated with tumorigenesis.

PERSPECTIVES

VIRUSES CAN USE VESICLES TO EXPORT THEIR FUNCTIONAL miRNAs

Pegtel et al. (2010) were the first ones (and, to our knowledge, the only ones together with Meckes et al., 2010) to have demonstrated that virus-infected cells package virus-encoded RNAs, and specifically viral miRNAs, into exosomes which are exported into the extracellular space and eventually delivered to recipient, non-infected cells, favoring the repression of specifically important mRNA targets. EBV is a clear example of a virus that utilizes the exosome pathway for the selective secretion of viral and cellular proteins and miRNAs that likely participate in cell-to-cell communication in the absence of virus production, potentially modulating cell function.

As confirming proof, Pegtel et al. (2010) reported that EBV-infected activated B cells secrete exosomes containing viral miRNAs shown to be delivered and actively internalized by monocyte-derived dendritic cells in co-culture. In particular, the copy number of EBV-miRNA BART1-5p was consistently higher than other EBV-miRNAs and its level increased fourfold after additional 24 h co-culture. This resulted in a dose-dependent, miRNA-mediated repression of confirmed EBV target genes. More specifically, the viral miRNA BHRF1-3 was shown to suppress the expression of the immunostimulatory gene CXCL11 [Chemokine (C-X-C motif) ligand 11] and this repression was proven to be dependent on the amount of exosomes carrying the miRNA and was not recipient cell-type-specific. In addition, expression of EBV-miRNAs in EBV-infected circulating B cells was also investigated. The data collected suggested that in asymptomatic patients BART miRNAs are expressed by latently infected circulating B cells as well as present in non-infected non-B cells, supporting the possibility of miRNA transfer in vivo. This further supported the proposal that exosomes could most likely serve as deliverers of small RNA due to their specialized biogenesis and presumed entry route (Zomer et al., 2010).

Later evidence showed that EBV-encoded miRNAs have been detected in exosomes from EBV-infected NPC cells, together with the LMP1 protein and other signal transduction molecules (Meckes et al., 2010), in accordance to other studies proving the presence of cellular miRNAs in tumor-derived exosomes (Taylor and Gercel-Taylor, 2008; Kharaziha et al., 2012; Palma et al., 2012).

Furthermore, differences detected in the levels of intracellular and exosomial miRNAs, in addition to differences even in the amount of enrichment between the individual exosomal miRNAs, suggest that some viral miRNAs might be specifically intended and selected to be packaged into exosomes and exert their functions in cells other than those producing them (Klibi et al., 2009; Meckes et al., 2010; Pegtel et al., 2010). Moreover, exosomes may also deliver cellular components of the RNA-induced silencing complex (RISC) to enhance viral miRNA function (Gibbings et al., 2009).

These results were greatly motivated by the assumption that exosomal exportation of miRNAs in general may have a fundamental role in intercellular communication despite the lack of concrete evidence (Valadi et al., 2007; Skog et al., 2008; Théry et al., 2009).

Although functional significance of all these phenomena requires further investigation, these results suggest that a cellular miRNA-loading mechanism may exist to direct specific miRNAs into intraluminal vesicles of multivesicular endosomes (MVEs) which could explain why exogenous exosomal miRNAs are capable of repressing targets in recipient cells at new subcellular compartments for RNAi activity such as late endosomes (Morelli et al., 2004; Stern-Ginossar et al., 2007; Gibbings et al., 2009). Figure 1 depicts all the potential ways in which viruses could exploit extracellular particles to convey their miRNAs to non-infected recipient cells.

FIGURE 1.

FIGURE 1

Open in a new tab

Summary model of plausible mechanisms for export and functional delivery of viral miRNAs. The image depicts the possible means of transcription, packaging, and functional delivery of viral miRNAs during an infection. Virus-encoded miRNAs are transcribed by the infected cell (A). They could exploit various channels to reach extracellular space and, eventually, be delivered to recipient non-infected cells: inside apoptotic bodies after cell death (B), packaged into exosomes (C), or HDL/LDL molecules or even bound to AGO2 (D). Viral miRNAs may be uptaken by non-infected cells where they could exert their regulatory functions (E).

FUNCTIONAL ANALYSIS OF CIRCULATING VIRAL miRNAs

The correct identification of targets is fundamental to determine miRNA function. Computational miRNA target prediction is still a big challenge, mostly due to the fact that our knowledge about the mechanisms and the molecular rules of miRNA target recognition is still incomplete (Bartel, 2009). Nevertheless, there are many computational tools available online, which allow to identify the most probable miRNA targets and to uncover non-trivial relationships between miRNAs and other molecular actors (Cascione et al., 2013). These tools collect and integrate heterogeneous miRNA-related data retrieved from different sources, such as target prediction tools and expression profiles of miRNAs and mRNAs, in order to infer miRNA functions and produce general models of miRNA-mediated regulation in the context of complex processes. Few tools are available specifically for the analysis of viral miRNAs and they are limited to the prediction of new miRNAs and targets. RepTar and vHoT are databases of predicted interspecies interactions between viral miRNA and host genomes, while ViTa is a database containing predictions of host miRNA targets on viruses (Hsu et al., 2007; Elefant et al., 2011; Kim et al., 2012). miRiam is a software that has been used to predict potential human targets for viral miRNAs (Laganà et al., 2010). Finally, VMir and Vir-Mir are tools for the prediction of novel virus-encoded miRNAs (Li et al., 2008; Grundhoff, 2011). In regard to functional analysis, despite the lack of specific programs for viral miRNAs, general miRNA tools can be successfully applied to the study of viral miRNAs as well. A very recent study shows that the predicted targets of the 135 known viral miRNAs in human viruses and of 6809 putative miRNAs encoded by 23 human viruses, as predicted by Vir-Mir, are enriched for specific host pathways whose targeting is likely beneficial to the virus, such as cancer, axon guidance, ErbB, mitogen-activated protein kinase (MAPK), and wingless-type MMTV integration site family (Wnt) signaling (Carl et al., 2013). The authors performed a functional enrichment analysis by comparing each gene target set with an annotated functional gene set corresponding to KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways and Gene Ontology biological processes. As further proof of principle, we used miRiam to predict the potential targets of EBV miRNAs in which exosomes are particularly enriched, as reported by Pegtel et al. (2010) (miR-BHRF1-1/1-2-3p and miR-BART1-3p/5p/-2-3p). Then, we used the tool ingenuity pathway analysis (IPA) to perform a functional enrichment analysis of the predicted targets (http://www.ingenuity.com). The results show that subsets of the targets are significantly involved in cancer pathways, in particular leiomyomatosis, and mesenchymal tumors, for which a connection with EBV had already been described (Cheuk et al., 2002; Monforte-Muñoz et al., 2003; Deyrup et al., 2006; Sunde et al., 2010). Other significant pathways include WNT/B-catenin signaling, interleukin 8 (IL-8) signaling, and P53 pathway (P < 0.0001), also previously described as related to EBV infections (Morrison et al., 2003; Everly et al., 2004; Ren et al., 2004; Webb et al., 2008; Forte and Luftig, 2009; Husaini et al., 2011; QingLing et al., 2011). The predicted targets are also enriched in GO terms such as cell death and survival and cell cycle (P < 0.04). Furthermore, although the significance of the P-value is borderline (P < 0.4), it is worth to mention that the top tox functions reported by IPA include increased levels of alkaline phosphatase and LDH, tumour-marker characteristics which have been reported to be significant prognostic factors in metastatic NPC, often associated wih EBV infection (Jin et al., 2012). Table 1 summarizes the most significant associations.

Table 1.

Functional enrichment analysis of circulating EBV miRNAs’ predicted targets.

P-Value
Selected canonical pathways
Molecular mechanisms of cancer 5.27 × 10-11
PPARα/RXRα activation 9.39 × 10-6
Wnt/β-catenin signaling 1.25 × 10-5
p53 signaling 6.73 × 10-5
IL-8 signaling 1.56 × 10-4
Selected molecular and cellular functions
Cell morphology <3.6 × 10-2
Cell death and survival <3.72 × 10-2
Cell cycle <4.09 × 10-2
Selected diseases and disorders: cancer
Leiomyomatosis 1.21 × 10-5
Cell transformation 2.60 × 10-3
Growth of tumor 5.14 × 10-3
Mesenchymal tumor 8.31 × 10-3
Selected tox functions (Clinical Chemistry and Hematology)
Decreased levels of albumin 1.37 × 10-1
Increased levels of alkaline phosphatase 2.21 × 10-1
Increased levels of albumin 3.70 × 10-1
Increased levels of LDH 3.70 × 10-1
Open in a new tab

The table summarizes the most relevant results, particularly associated to EBV infection, of the functional analysis conducted using the software IPA. Results are organized in categories. For each category, the most significant terms, together with their P-Values, are displayed. EBV-encoded miRNAs in which exosomes are particularly enriched were selected (miR-BHRF1-1/1-2-3p and miR-BART1-3p/5p/-2-3p) and their targets predicted using the tool miRiam. The top scoring targets were given as input to IPA.

These few examples clearly indicate that miRNA functional analysis tools can be of great help in studying the effects of circulating viral miRNAs, allowing the production of plausible hypotheses about their function and involvement in crucial cellular pathways, encouraging the development of more specific tools for computational investigation of cellular and extracellular viral miRNA.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

REFERENCES

  1. Alexandrov P. N., Dua P., Hill J. M., Bhattacharjee S., Zhao Y., Lukiw W. J. (2012) microRNA (miRNA) speciation in Alzheimer’s disease (AD) cerebrospinal fluid (CSF) and extracellular fluid (ECF). Int. J. Biochem. Mol. Biol. 3 365–373 [PMC free article] [PubMed] [Google Scholar]
  2. Arroyo J. D., Chevillet J. R., Kroh E. M., Ruf I. K., Pritchard C. C., Gibson D. F., et al. (2011) Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc. Natl. Acad. Sci. U.S.A. 108 5003–5008 10.1073/pnas.1019055108 [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bartel D. P. (2009) MicroRNAs: target recognition and regulatory functions. Cell 136 215–233 10.1016/j.cell.2009.01.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bauman Y., Nachmani D., Vitenshtein A., Tsukerman P., Drayman N., Stern-Ginossar N., et al. (2011) An identical miRNA of the human JC and BK polyoma viruses targets the stress-induced ligand ULBP3 to escape immune elimination. Cell Host Microbe 9 93–102 10.1016/j.chom.2011.01.008 [DOI] [PubMed] [Google Scholar]
  5. Boon R. A., Vickers K. C. (2013) Intercellular transport of microRNAs. Arterioscler. Thromb. Vasc. Biol. 33 186–192 10.1161/ATVBAHA.112.300139 [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Carl J. W., Jr., Trgovcich J., Hannenhalli S. (2013) Widespread evidence of viral miRNAs targeting host pathways.BMC Bioinformatics 14(Suppl.2): S3 10.1186/1471-2105-14-S2-S3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cascione L., Ferro A., Giugno R., Laganà A., Pigola G., Pulvirenti A., et al. (2013) Elucidating the role of microRNAs in cancer through data mining techniques. Adv. Exp. Med. Biol. 774 291–315 10.1007/978-94-007-5590-1_15 [DOI] [PubMed] [Google Scholar]
  8. Cheuk W., Li P. C., Chan J. K. (2002) Epstein–Barr virus-associated smooth muscle tumour: a distinctive mesenchymal tumour of immunocompromised individuals. Pathology 34 245–249 10.1080/00313020220131309 [DOI] [PubMed] [Google Scholar]
  9. Choy E. Y., Siu K. L., Kok K. H., Lung R. W., Tsang C. M., To K. F., et al. (2008) An Epstein–Barr virus-encoded microRNA targets PUMA to promote host cell survival. J. Exp. Med. 205 2551–2560 10.1084/jem.20072581 [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Croce C. M. (2009) Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 10 704–714 10.1038/nrg2634 [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Cullen B. R. (2006). Viruses and microRNAs. Nat. Genet. 38(Suppl.) S25–S30 10.1038/ng1793 [DOI] [PubMed] [Google Scholar]
  12. daSilva L. L., Sougrat R., Burgos P. V., Janvier K., Mattera R., Bonifacino J. S. (2009). Human immunodeficiency virus type 1 Nef protein targets CD4 to the multivesicular body pathway. J. Virol. 83 6578–6590 10.1128/JVI.00548-09 [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. de Gassart A., Geminard C., Fevrier B., Raposo G., Vidal M. (2003). Lipid raft-associated protein sorting in exosomes. Blood 102 4336–4344 10.1182/blood-2003-03-0871 [DOI] [PubMed] [Google Scholar]
  14. Deyrup A. T., Lee V. K., Hill C. E., Cheuk W., Toh H. C., Kesavan S., et al. (2006). Epstein–Barr virus-associated smooth muscle tumors are distinctive mesenchymal tumors reflecting multiple infection events: a clinicopathologic and molecular analysis of 29 tumors from 19 patients. Am. J. Surg. Pathol. 30 75–82 10.1097/01.pas.0000178088.69394.7b [DOI] [PubMed] [Google Scholar]
  15. Eacker S. M., Dawson T. M., Dawson V. L. (2009). Understanding microRNAs in neurodegeneration. Nat. Rev. Neurosci. 10 837–841 10.1038/nrn2726 [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Elefant N., Berger A., Shein H., Hofree M., Margalit H., Altuvia Y. (2011). RepTar: a database of predicted cellular targets of host and viral miRNAs. Nucleic Acids Res. 39 D188–D194 10.1093/nar/gkq1233 [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Everly D. N., Jr., Kusano S., Raab-Traub N. (2004). Accumulation of cytoplasmic beta-catenin and nuclear glycogen synthase kinase 3beta in Epstein–Barr virus-infected cells. J. Virol. 78 11648–11655 10.1128/JVI.78.21.11648-11655.2004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Fayyad-Kazan H., Bitar N., Najar M., Lewalle P., Fayyad-Kazan M., Badran R., et al. (2013). Circulating miR-150 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemia. J. Transl. Med. 11 31 10.1186/1479-5876-11-31 [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Forte E., Luftig M. A. (2009). MDM2-dependent inhibition of p53 is required for Epstein–Barr virus B-cell growth transformation and infected-cell survival. J. Virol. 83 2491–2499 10.1128/JVI.01681-08 [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Gallo A., Tandon M., Alevizos I., Illei G. G. (2012). The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. PLoS ONE 7:e30679 10.1371/journal.pone.0030679 [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Gibbings D. J., Ciaudo C., Erhardt M., Voinnet O. (2009). Multivesicular bodies associate with components of miRNA effector complexes and modulate miRNA activity. Nat. Cell Biol. 11 1143–1149 10.1038/ncb1929 [DOI] [PubMed] [Google Scholar]
  22. Gottwein E., Mukherjee N., Sachse C., Frenzel C., Majoros W. H., Chi J. T., et al. (2007). A viral microRNA functions as an orthologue of cellular miR-155. Nature 450 1096–1099 10.1038/nature05992 [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Gould S. J., Booth A. M., Hildreth J. E. (2003). The Trojan exosome hypothesis. Proc. Natl. Acad. Sci. U.S.A. 100 10592–10597 10.1073/pnas.1831413100 [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Grundhoff A. (2011). Computational prediction of viral miRNAs. Methods Mol. Biol. 721 143–152 10.1007/978-1-61779-037-9_8 [DOI] [PubMed] [Google Scholar]
  25. György B., Szabó T. G., Pásztói M., Pál Z., Misják P., Aradi B., et al. (2011). Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell. Mol. Life Sci. 68 2667–2688 10.1007/s00018-011-0689-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Hanke M., Hoefig K., Merz H., Feller A. C., Kausch I., Jocham D., et al. (2010). A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol. Oncol. 28 655–661 10.1016/j.urolonc.2009.01.027 [DOI] [PubMed] [Google Scholar]
  27. Hergenreider E., Heydt S., Tréguer K., Boettger T., Horrevoets A. J., Zeiher A. M., et al. (2012). Atheroprotective communication between endo- thelial cells and smooth muscle cells through miRNAs. Nat. Cell Biol. 14 249–256 10.1038/ncb2441 [DOI] [PubMed] [Google Scholar]
  28. Hilton C., Karpe F. (2013). Circulating microRNAs: what is their relevance? Clin. Chem. 59 729–731 10.1373/clinchem.2013.203166 [DOI] [PubMed] [Google Scholar]
  29. Hosseini H. M., Fooladi A. A., Nourani M. R., Ghanezadeh F. (2013). The role of exosomes in infectious diseases. Inflamm. Allergy Drug Targets 12 29–37 10.2174/1871528111312010005 [DOI] [PubMed] [Google Scholar]
  30. Houzet L., Jeang K. T. (2011). MicroRNAs and human retroviruses. Biochim. Biophys. Acta 1809 686–693 10.1016/j.bbagrm.2011.05.009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Hsu P. W., Lin L. Z., Hsu S. D., Hsu J. B., Huang H. D. (2007). ViTa: prediction of host microRNAs targets on viruses. Nucleic Acids Res. 35 D381–D385 10.1093/nar/gkl1009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Husaini R., Ahmad M, Soo-Beng Khoo A. (2011). Epstein–Barr virus latent membrane protein LMP1 reduces p53 protein levels independent of the PI3K-Akt pathway. BMC Res. Notes 4:551 10.1186/1756-0500-4-551 [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Hussain M., Taft R. J., Asgari S. (2008). An insect virus-encoded microRNA regulates viral replication. J. Virol. 82 9164–9170 10.1128/JVI.01109-08 [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Izquierdo-Useros N., Naranjo-Gómez M., Archer J., Hatch S. C., Erkizia I., Blanco J., et al. (2009). Capture and transfer of HIV-1 particles by mature dendritic cells converges with the exosome-dissemination pathway. Blood 113 2732–2741 10.1182/blood-2008-05-158642 [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Izquierdo-Useros N., Naranjo-Gómez M., Erkizia I., Puertas M. C., Borràs F. E., Blanco J., et al. (2010). HIV and mature dendritic cells: Trojan exosomes riding the Trojan horse? PLoS Pathog. 6:e1000740 10.1371/journal.ppat.1000740 [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Jin Y., Cai X. Y., Cai Y. C., Cao Y., Xia Q., Tan Y. T., et al. (2012). To build a prognostic score model containing indispensible tumour markers for metastatic nasopharyngeal carcinoma in an epidemic area. Eur. J. Cancer 48 882–888 10.1016/j.ejca.2011.09.004 [DOI] [PubMed] [Google Scholar]
  37. Kaul D., Ahlawat A., Gupta S. D. (2009). HIV-1 genome-encoded hiv1-mir-H1 impairs cellular responses to infection. Mol. Cell. Biochem. 323 143–148 10.1007/s11010-008-9973-4 [DOI] [PubMed] [Google Scholar]
  38. Kaye K. M., Izumi K. M., Kieff E. (1993). Epstein–Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc. Natl. Acad. Sci. U.S.A. 90 9150–9154 10.1073/pnas.90.19.9150 [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Kharaziha P., Ceder S., Li Q., Panaretakis T. (2012). Tumor cell-derived exosomes: a message in a bottle. Biochem. Biophys. Res. Commun. 423 642–646 10.1016/j.bbcan.2012.03.006 [DOI] [PubMed] [Google Scholar]
  40. Kim H., Park S., Min H., Yoon S. (2012). vHoT: a database for predicting interspecies interactions between viral microRNA and host genomes. Arch. Virol. 157 497–501 10.1007/s00705-011-1181-y [DOI] [PubMed] [Google Scholar]
  41. Kincaid R. P., Burke J. M., Sullivan C. S. (2012). RNA virus microRNA that mimics a B-cell oncomiR. Proc. Natl. Acad. Sci. U.S.A. 109 3077–3082 10.1073/pnas.1116107109 [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Kincaid R. P., Sullivan C. S. (2012). Virus-encoded microRNAs: an overview and a look to the future. PLoS Pathog. 8:e1003018 10.1371/journal.ppat.1003018 [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Klase Z., Winograd R., Davis J., Carpio L., Hildreth R., Heydarian M., et al. (2009). HIV-1 TAR miRNA protects against apoptosis by altering cellular gene expression. Retrovirology 6:18 10.1186/1742-4690-6-18 [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Klibi J., Niki T., Riedel A., Pioche-Durieu C., Souquere S., Rubinstein E., et al. (2009). Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein–Barr virus-infected nasopharyngeal carcinoma cells. Blood 113 1957–1966 10.1182/blood-2008-02-142596 [DOI] [PubMed] [Google Scholar]
  45. Laganà A., Forte S., Russo F., Giugno R., Pulvirenti A., Ferro A. (2010). Prediction of human targets for viral-encoded microRNAs by thermodynamics and empirical constraints. J. RNAi Gene Silencing 6 379–385 [PMC free article] [PubMed] [Google Scholar]
  46. Lee S. H., Kalejta R. F., Kerry J., Semmes O. J., O’Connor C. M., Khan Z., et al. (2012). BclAF1 restriction factor is neutralized by proteasomal degradation and microRNA repression during human cytomegalovirus infection. Proc. Natl. Acad. Sci. U.S.A. 109 9575–9580 10.1073/pnas.1207496109 [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Li S. C., Shiau C. K., Lin W. C. (2008). Vir-Mir db: prediction of viral microRNA candidate hairpins. Nucleic Acids Res. 36 D184–D189 10.1093/nar/gkm610 [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Mack M., Kleinschmidt A., Brühl H., Klier C., Nelson P. J., Cihak J., et al. (2000). Transfer of the chemokine receptor CBR5 between cells by membrane-derived microparticles: a mechanism for cellular human immunodeficiency virus 1 infection. Nat. Med. 6 769–775 10.1038/77498 [DOI] [PubMed] [Google Scholar]
  49. Marquitz A. R., Mathur A., Nam C. S., Raab-Traub N. (2011). The Epstein–Barr Virus BART microRNAs target the pro-apoptotic protein Bim. Virology 412 392–400 10.1016/j.virol.2011.01.028 [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Masciopinto F., Giovani C., Campagnoli S., Galli-Stampino L., Colombatto P., Brunetto M., et al. (2004). Association of hepatitis C virus envelope proteins with exosomes. Eur. J. Immunol. 34 2834–2842 10.1002/eji.200424887 [DOI] [PubMed] [Google Scholar]
  51. Meckes D. G., Jr., Raab-Traub N. (2011). Microvesicles and viral infection. J. Virol. 85 12844–12854 10.1128/JVI.05853-11 [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Meckes D. G., Jr., Shair K. H., Marquitz A. R., Kung C. P., Edwards R. H., Raab-Traub N. (2010). Human tumor virus utilizes exosomes for intercellular communication. Proc. Natl. Acad. Sci. U.S.A. 107 20370–20375 10.1073/pnas.1014194107 [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Mitchell P. S., Parkin R. K., Kroh E. M., Fritz B. R., Wyman S. K., Pogosova-Agadjanyan E. L., et al. (2008). Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U.S.A. 105 10513–10518 10.1073/pnas.0804549105 [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Monforte-Muñoz H., Kapoor N., Saavedra J. A. (2003). Epstein–Barr virus-associated leiomyomatosis and posttransplant lymphoproliferative disorder in a child with severe combined immunodeficiency: case report and review of the literature. Pediatr. Dev. Pathol. 6 449–457 10.1007/s10024-003-8096-x [DOI] [PubMed] [Google Scholar]
  55. Morelli A. E., Larregina A. T., Shufesky W. J., Sullivan M. L., Stolz D. B., Papworth G. D., et al. (2004). Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells. Blood 104 3257–3266 10.1182/blood-2004-03-0824 [DOI] [PubMed] [Google Scholar]
  56. Morrison J. A., Klingelhutz A. J., Raab-Traub N. (2003). Epstein–Barr virus latent membrane protein 2A activates beta-catenin signaling in epithelial cells. J. Virol. 77 12276–12284 10.1128/JVI.77.22.12276-12284.2003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Novellino L., Rossi R. L., Bonino F., Cavallone D., Abrignani S., Pagani M., et al. (2012). Circulating hepatitis B surface antigen particles carry hepatocellular microRNAs. PLoS ONE 7:e31952 10.1371/journal.pone.0031952 [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Ohshima K., Inoue K., Fujiwara A., Hatakeyama K., Kanto K., Watanabe Y., et al. (2010). Let-7 microRNA family is selectively secreted into the extracellular environment via exosomes in a metastatic gastric cancer cell line. PLoS ONE 5:e13247 10.1371/journal.pone.0013247 [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Palma J., Yaddanapudi S. C., Pigati L., Havens M. A., Jeong S., Weiner G. A., et al. (2012). MicroRNAs are exported from malignant cells in customized particles. Nucleic Acids Res. 40 9125–9138 10.1093/nar/gks656 [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Pegtel D. M., Cosmopoulos K., Thorley-Lawson D. A., van Eijndhoven M. A., Hopmans E. S., Lindenberg J. L., et al. (2010). Functional delivery of viral miRNAs via exosomes. Proc. Natl. Acad. Sci. U.S.A. 107 6328–6333 10.1073/pnas.0914843107 [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Pfeffer S., Zavolan M., Grässer F. A., Chien M., Russo J. J., Ju J., et al. (2004). Identification of virus-encoded microRNAs. Science 304 734–736 10.1126/science.1096781 [DOI] [PubMed] [Google Scholar]
  62. Pigati L., Yaddanapudi S. C., Iyengar R., Kim D. J., Hearn S. A., Danforth D., et al. (2010). Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS ONE 5:e13515 10.1371/journal.pone.0013515 [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Plazolles N., Humbert J. M., Vachot L., Verrier B., Hocke C., Halary F. (2011). Pivotal advance: the promotion of soluble DC-SIGN release by inflammatory signals and its enhancement of cytomegalovirus-mediated cis-infection of myeloid dendritic cells. J. Leukoc. Biol. 89 329–342 10.1189/jlb.0710386 [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. QingLing Z., LiNa Y., Li L., Shuang W., YuFang Y., Yi D., et al. (2011). LMP1 antagonizes WNT/(β -catenin signalling through inhibition of WTX and promotes nasopharyngeal dysplasia but not tumourigenesis in LMP1(B95-8) transgenic mice. J. Pathol. 223 574–583 [DOI] [PubMed] [Google Scholar]
  65. Rayner K. J., Hennessy E. J. (2013). Extracellular communication via microRNA: lipid particles have a new message. J. Lipid Res. 54 1174–1181 10.1194/jlr.R034991 [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Ren Q., Sato H., Murono S., Furukawa M., Yoshizaki T. (2004). Epstein–Barr virus (EBV) latent membrane protein 1 induces interleukin-8 through the nuclear factor-kappa B signaling pathway in EBV-infected nasopharyngeal carcinoma cell line. Laryngoscope 114 855–859 10.1097/00005537-200405000-00012 [DOI] [PubMed] [Google Scholar]
  67. Russo F., Di Bella S., Nigita G., Macca V., Laganà A., Giugno R., et al. (2012). miRandola: extracellular circulating microRNAs database. PLoS ONE 7:e47786 10.1371/journal.pone.0047786 [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Seo G. J., Chen C. J., Sullivan C. S. (2009). Merkel cell polyomavirus encodes a microRNA with the ability to autoregulate viral gene expression. Virology 383 183–187 10.1016/j.virol.2008.11.001 [DOI] [PubMed] [Google Scholar]
  69. Seto E., Moosmann A., Grömminger S., Walz N., Grundhoff A., Hammerschmidt W. (2010). Micro RNAs of Epstein–Barr virus promote cell cycle progression and prevent apoptosis of primary human B cells. PLoS Pathog. 6:e1001063 10.1371/journal.ppat.1001063 [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Skog J., Würdinger T., van Rijn S., Meijer D. H., Gainche L., Sena-Esteves M., et al. (2008). Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat. Cell Biol. 10 1470–1476 10.1038/ncb1800 [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Stern-Ginossar N., Elefant N., Zimmermann A., Wolf D. G., Saleh N., Biton M., et al. (2007). Host immune system gene targeting by a viral miRNA. Science 317 376–381 10.1126/science.1140956 [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Suffert G., Malterer G., Hausser J., Viiliäinen J., Fender A., Contrant M., et al. (2011). Kaposi’s sarcoma herpesvirus microRNAs target caspase 3 and regulate apoptosis. PLoS Pathog. 7:e1002405 10.1371/journal.ppat.1002405 [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Sullivan C. S. (2008). New roles for large and small viral RNAs in evading host defences. Nat. Rev. Genet. 9 503–507 10.1038/nrg2349 [DOI] [PubMed] [Google Scholar]
  74. Sullivan C. S., Grundhoff A. T., Tevethia S., Pipas J. M., Ganem D. (2005). SV40-encoded microRNAs regulate viral gene expression and reduce susceptibility to cytotoxic T cells. Nature 435 682–686 10.1038/nature03576 [DOI] [PubMed] [Google Scholar]
  75. Sunde J., Chetty-John S., Shlobin O. A., Boice C. R. (2010). Epstein–Barr virus-associated uterine leiomyosarcoma in an adult lung transplant patient. Obstet. Gynecol. 115(Pt 2) 434–436 10.1097/AOG.0b013e3181c51ed0 [DOI] [PubMed] [Google Scholar]
  76. Taylor D. D., Gercel-Taylor C. (2008). MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol. Oncol. 110 13–21 10.1016/j.ygyno.2008.04.033 [DOI] [PubMed] [Google Scholar]
  77. Temme S., Eis-Hübinger A. M., McLellan A. D., Koch N. (2010). The herpes simplex virus-1 encoded glycoprotein B diverts HLA-DR into the exosome pathway. J. Immunol. 184 236–243 10.4049/jimmunol.0902192 [DOI] [PubMed] [Google Scholar]
  78. tenOever B. R. (2013). RNA viruses and the host microRNA machinery. Nat. Rev. Microbiol. 11 169–180 10.1038/nrmicro2971 [DOI] [PubMed] [Google Scholar]
  79. Théry C., Ostrowski M., Segura E. (2009). Membrane vesicles as conveyors of immune responses. Nat. Rev. Immunol. 9 581–593 10.1038/nri2567 [DOI] [PubMed] [Google Scholar]
  80. Turchinovich A., Weiz L., Langheinz A., Burwinkel B. (2011). Characterization of extracellular circulating microRNA. Nucleic Acids Res. 39 7223–7233 10.1093/nar/gkr254 [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. Valadi H., Ekström K., Bossios A., Sjöstrand M., Lee J. J, Lötvall J. O. (2007). Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 9 654–659 10.1038/ncb1596 [DOI] [PubMed] [Google Scholar]
  82. Vickers K. C., Remaley A. T. (2012). Lipid-based carriers of microRNAs and intercellular communication. Curr. Opin. Lipidol. 23 91–97 10.1097/MOL.0b013e328350a425 [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Wang C., Yang C., Chen X., Yao B., Yang C., Zhu C., et al. (2011). Altered profile of seminal plasma microRNAs in the molecular diagnosis of male infertility. Clin. Chem. 57 1722–1731 10.1373/clinchem.2011.169714 [DOI] [PubMed] [Google Scholar]
  84. Wang D., Liebowitz D., Kieff E. (1985). An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 43(Pt 2) 831–840 10.1016/0092-8674(85)90256-9 [DOI] [PubMed] [Google Scholar]
  85. Webb N., Connolly G., Tellam J., Yap A. S., Khanna R. (2008). Epstein–Barr virus associated modulation of Wnt pathway is not dependent on latent membrane protein-1. PLoS ONE 3:e3254 10.1371/journal.pone.0003254 [DOI] [PMC free article] [PubMed] [Google Scholar]
  86. Wurdinger T., Gatson N. N., Balaj L., Kaur B., Breakefield X. O., Pegtel D. M. (2012). Extracellular vesicles and their convergence with viral pathways. Adv. Virol. 2012 767694 10.1155/2012/767694 [DOI] [PMC free article] [PubMed] [Google Scholar]
  87. You X., Zhang Z., Fan J., Cui Z., Zhang X. E. (2012). Functionally orthologous viral and cellular microRNAs studied by a novel dual-fluorescent reporter system. PLoS ONE 7:e36157 10.1371/journal.pone.0036157 [DOI] [PMC free article] [PubMed] [Google Scholar]
  88. Zeng R. C., Zhang W., Yan X. Q., Ye Z. Q., Chen E. D., Huang D. P., et al. (2013). Down-regulation of miRNA-30a in human plasma is a novel marker for breast cancer. Med. Oncol. 30 477 10.1007/s12032-013-0477-z [DOI] [PubMed] [Google Scholar]
  89. Zernecke A., Bidzhekov K., Noels H., Shagdarsuren E., Gan L., Denecke B., et al. (2009). Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci. Signal. 2 ra81 10.1126/scisignal.2000610 [DOI] [PubMed] [Google Scholar]
  90. Zhang Y., Liu D., Chen X., Li J., Li L., Bian Z., et al. (2010). Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol. Cell 39 133–144 10.1016/j.molcel.2010.06.010 [DOI] [PubMed] [Google Scholar]
  91. Zhao Y., Xu H., Yao Y., Smith L. P., Kgosana L., Green J., et al. (2011). Critical role of the virus-encoded microRNA-155 ortholog in the induction of Marek’s disease lymphomas. PLoS Pathog. 7:e1001305 10.1371/journal.ppat.1001305 [DOI] [PMC free article] [PubMed] [Google Scholar]
  92. Zhou Q., Li M., Wang X., Li Q., Wang T., Zhu Q., et al. (2012). Immune-related microRNAs are abundant in breast milk exosomes. Int. J. Biol. Sci. 8 118–123 10.7150/ijbs.8.118 [DOI] [PMC free article] [PubMed] [Google Scholar]
  93. Zomer A., Vendrig T., Hopmans E. S., van Eijndhoven M., Middeldorp J. M., Pegtel D. M. (2010). Exosomes: fit to deliver small RNA. Commun. Integr. Biol. 3 447–450 10.4161/cib.3.5.12339 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Frontiers in Genetics are provided here courtesy of Frontiers Media SA

RESOURCES